FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027367061> ?p ?o ?g. }

• W2027367061 endingPage "129" @default.
• W2027367061 startingPage "123" @default.
• W2027367061 abstract "Objectives To evaluate the efficacy and safety of phosphodiesterase-5 (PDE-5) inhibitors for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. Methods Randomized controlled trials were identified and extracted from MEDLINE, Embase, Cochrane Central, and relevant reference lists. The database search, quality assessment, and data extraction were independently performed by 2 reviewers. Heterogeneity was analyzed using the chi-square test and I2 test. If lacking of heterogeneity, fixed-effects models were used for the meta-analysis, otherwise random-effects models were used. Results A total of 5 studies (11 randomized controlled trials) were identified from the search strategy. Compared with placebo, short-term trials (≤12 weeks) indicated that PDE-5 inhibitors significantly improved the International Prostate Symptom Score (mean difference −2.60, 95% confidence interval [CI] −3.12 to −2.07; P < .00001), and statistical significance was observed in the International Prostate Symptom Score irritative and obstructive subscore, International Prostate Symptom Score quality of life and erectile function. However, no statistically significant difference was detected in maximal urinary flow rate (mean difference 0.21, 95% CI −0.21-0.64; P = .32) and postvoid residual urine volume (mean difference 0.09, 95% CI −4.71-4.89; P = .80). No statistically significant difference was found between the 2 groups in the incidence of serious adverse events (relative risk 0.52, 95% CI 0.25-1.07; P = .07), despite that adverse event with a greater incidence was detected in the PDE-5 group (relative risk 1.87, 95% CI 1.31-2.68; P = .0005). Conclusions As the first-line treatment of erectile dysfunction, the PDE-5 inhibitor is also effective and safe for lower urinary tract symptoms secondary to benign prostatic hyperplasia. It could be considered as the first-line treatment in the future for the treatment of patients with comorbid benign prostatic hyperplasia and erectile dysfunction. To evaluate the efficacy and safety of phosphodiesterase-5 (PDE-5) inhibitors for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. Randomized controlled trials were identified and extracted from MEDLINE, Embase, Cochrane Central, and relevant reference lists. The database search, quality assessment, and data extraction were independently performed by 2 reviewers. Heterogeneity was analyzed using the chi-square test and I2 test. If lacking of heterogeneity, fixed-effects models were used for the meta-analysis, otherwise random-effects models were used. A total of 5 studies (11 randomized controlled trials) were identified from the search strategy. Compared with placebo, short-term trials (≤12 weeks) indicated that PDE-5 inhibitors significantly improved the International Prostate Symptom Score (mean difference −2.60, 95% confidence interval [CI] −3.12 to −2.07; P < .00001), and statistical significance was observed in the International Prostate Symptom Score irritative and obstructive subscore, International Prostate Symptom Score quality of life and erectile function. However, no statistically significant difference was detected in maximal urinary flow rate (mean difference 0.21, 95% CI −0.21-0.64; P = .32) and postvoid residual urine volume (mean difference 0.09, 95% CI −4.71-4.89; P = .80). No statistically significant difference was found between the 2 groups in the incidence of serious adverse events (relative risk 0.52, 95% CI 0.25-1.07; P = .07), despite that adverse event with a greater incidence was detected in the PDE-5 group (relative risk 1.87, 95% CI 1.31-2.68; P = .0005). As the first-line treatment of erectile dysfunction, the PDE-5 inhibitor is also effective and safe for lower urinary tract symptoms secondary to benign prostatic hyperplasia. It could be considered as the first-line treatment in the future for the treatment of patients with comorbid benign prostatic hyperplasia and erectile dysfunction." @default.
• W2027367061 created "2016-06-24" @default.
• W2027367061 creator A5030863883 @default.
• W2027367061 creator A5044002777 @default.
• W2027367061 creator A5074725449 @default.
• W2027367061 creator A5085712319 @default.
• W2027367061 date "2011-01-01" @default.
• W2027367061 modified "2023-09-25" @default.
• W2027367061 title "Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis" @default.
• W2027367061 cites W1964629962 @default.
• W2027367061 cites W1964683861 @default.
• W2027367061 cites W1966649210 @default.
• W2027367061 cites W1981147501 @default.
• W2027367061 cites W1986031402 @default.
• W2027367061 cites W1986215651 @default.
• W2027367061 cites W1995256786 @default.
• W2027367061 cites W1996959886 @default.
• W2027367061 cites W1999691104 @default.
• W2027367061 cites W2005828296 @default.
• W2027367061 cites W2015122735 @default.
• W2027367061 cites W2023252283 @default.
• W2027367061 cites W2025969930 @default.
• W2027367061 cites W2050093658 @default.
• W2027367061 cites W2051838969 @default.
• W2027367061 cites W2053295331 @default.
• W2027367061 cites W2070170982 @default.
• W2027367061 cites W2074093603 @default.
• W2027367061 cites W2078469638 @default.
• W2027367061 cites W2081375755 @default.
• W2027367061 cites W2086063691 @default.
• W2027367061 cites W2097777344 @default.
• W2027367061 cites W2108148925 @default.
• W2027367061 cites W2109162604 @default.
• W2027367061 cites W2163525357 @default.
• W2027367061 cites W2167891855 @default.
• W2027367061 cites W2792142391 @default.
• W2027367061 doi "https://doi.org/10.1016/j.urology.2010.07.508" @default.
• W2027367061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21195830" @default.
• W2027367061 hasPublicationYear "2011" @default.
• W2027367061 type Work @default.
• W2027367061 sameAs 2027367061 @default.
• W2027367061 citedByCount "45" @default.
• W2027367061 countsByYear W20273670612012 @default.
• W2027367061 countsByYear W20273670612013 @default.
• W2027367061 countsByYear W20273670612014 @default.
• W2027367061 countsByYear W20273670612015 @default.
• W2027367061 countsByYear W20273670612016 @default.
• W2027367061 countsByYear W20273670612017 @default.
• W2027367061 countsByYear W20273670612018 @default.
• W2027367061 countsByYear W20273670612019 @default.
• W2027367061 countsByYear W20273670612020 @default.
• W2027367061 countsByYear W20273670612021 @default.
• W2027367061 crossrefType "journal-article" @default.
• W2027367061 hasAuthorship W2027367061A5030863883 @default.
• W2027367061 hasAuthorship W2027367061A5044002777 @default.
• W2027367061 hasAuthorship W2027367061A5074725449 @default.
• W2027367061 hasAuthorship W2027367061A5085712319 @default.
• W2027367061 hasConcept C121608353 @default.
• W2027367061 hasConcept C126322002 @default.
• W2027367061 hasConcept C126894567 @default.
• W2027367061 hasConcept C142724271 @default.
• W2027367061 hasConcept C168563851 @default.
• W2027367061 hasConcept C197934379 @default.
• W2027367061 hasConcept C204787440 @default.
• W2027367061 hasConcept C27081682 @default.
• W2027367061 hasConcept C2776235491 @default.
• W2027367061 hasConcept C2776478404 @default.
• W2027367061 hasConcept C2776547966 @default.
• W2027367061 hasConcept C2779478474 @default.
• W2027367061 hasConcept C28804328 @default.
• W2027367061 hasConcept C44249647 @default.
• W2027367061 hasConcept C71924100 @default.
• W2027367061 hasConcept C82789193 @default.
• W2027367061 hasConcept C95190672 @default.
• W2027367061 hasConceptScore W2027367061C121608353 @default.
• W2027367061 hasConceptScore W2027367061C126322002 @default.
• W2027367061 hasConceptScore W2027367061C126894567 @default.
• W2027367061 hasConceptScore W2027367061C142724271 @default.
• W2027367061 hasConceptScore W2027367061C168563851 @default.
• W2027367061 hasConceptScore W2027367061C197934379 @default.
• W2027367061 hasConceptScore W2027367061C204787440 @default.
• W2027367061 hasConceptScore W2027367061C27081682 @default.
• W2027367061 hasConceptScore W2027367061C2776235491 @default.
• W2027367061 hasConceptScore W2027367061C2776478404 @default.
• W2027367061 hasConceptScore W2027367061C2776547966 @default.
• W2027367061 hasConceptScore W2027367061C2779478474 @default.
• W2027367061 hasConceptScore W2027367061C28804328 @default.
• W2027367061 hasConceptScore W2027367061C44249647 @default.
• W2027367061 hasConceptScore W2027367061C71924100 @default.
• W2027367061 hasConceptScore W2027367061C82789193 @default.
• W2027367061 hasConceptScore W2027367061C95190672 @default.
• W2027367061 hasFunder F4320321001 @default.
• W2027367061 hasIssue "1" @default.
• W2027367061 hasLocation W20273670611 @default.
• W2027367061 hasOpenAccess W2027367061 @default.
• W2027367061 hasPrimaryLocation W20273670611 @default.
• W2027367061 hasRelatedWork W1978630268 @default.
• W2027367061 hasRelatedWork W2013357874 @default.

• next